• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Optimal two-stage designs for clinical trials with binary response.

作者信息

Thall P F, Simon R, Ellenberg S S, Shrager R

机构信息

Statistics/Computer & Information Systems Department, George Washington University, Washington, D.C. 20052.

出版信息

Stat Med. 1988 May;7(5):571-9. doi: 10.1002/sim.4780070504.

DOI:10.1002/sim.4780070504
PMID:3387716
Abstract

We present a simple two-stage design for a randomized clinical trial with dichotomous outcomes. It is based on a design of Ellenberg and Eisenberger which permits early acceptance of the null hypothesis after the first stage. We have optimized the design by minimizing the average expected sample size subject to constraints on the type 1 and type 2 errors. The resulting designs have maximum sample size only slightly larger than that of single stage trial, with 40-45 per cent of this maximum allocated to the first stage, and null hypothesis probability of early acceptance in excess of 0.60.

摘要

相似文献

1
Optimal two-stage designs for clinical trials with binary response.
Stat Med. 1988 May;7(5):571-9. doi: 10.1002/sim.4780070504.
2
A two-stage design for randomized trials with binary outcomes.用于二元结局随机试验的两阶段设计。
Control Clin Trials. 1987 Mar;8(1):20-8. doi: 10.1016/0197-2456(87)90022-5.
3
Optimal restricted two-stage designs.
Control Clin Trials. 1987 Jun;8(2):146-56. doi: 10.1016/0197-2456(87)90039-0.
4
Optimal designs for clinical trials with dichotomous responses.具有二分反应的临床试验的最优设计。
Stat Med. 1985 Oct-Dec;4(4):497-508. doi: 10.1002/sim.4780040410.
5
On design considerations and randomization-based inference for community intervention trials.关于社区干预试验的设计考量及基于随机化的推断
Stat Med. 1996 Jun 15;15(11):1069-92. doi: 10.1002/(SICI)1097-0258(19960615)15:11<1069::AID-SIM220>3.0.CO;2-Q.
6
Interim analysis and sample size reassessment.中期分析与样本量重新评估。
Biometrics. 2000 Dec;56(4):1170-6. doi: 10.1111/j.0006-341x.2000.01170.x.
7
Optimal adaptive two-stage designs for early phase II clinical trials.早期II期临床试验的最优适应性两阶段设计。
Stat Med. 2016 Apr 15;35(8):1257-66. doi: 10.1002/sim.6794. Epub 2015 Nov 3.
8
Estimation in flexible two stage designs.灵活两阶段设计中的估计
Stat Med. 2006 Oct 15;25(19):3366-81. doi: 10.1002/sim.2258.
9
Reasonable two-stage adaptive designs for single-arm phase II clinical trials.单臂II期临床试验的合理两阶段适应性设计。
Pharm Stat. 2018 Nov;17(6):770-780. doi: 10.1002/pst.1899. Epub 2018 Aug 30.
10
Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes.适用于带有生存时间结局的剂量探索研究的自适应最优设计。
AAPS J. 2017 Dec 28;20(1):24. doi: 10.1208/s12248-017-0166-5.

引用本文的文献

1
Response adaptive randomization design for a two-stage study with binary response.两阶段二分类反应研究的响应适应性随机分组设计。
J Biopharm Stat. 2023 Sep 3;33(5):575-585. doi: 10.1080/10543406.2023.2170399. Epub 2023 Feb 3.
2
Early-Phase Platform Trials: A New Paradigm for Dose Finding and Treatment Screening in the Era of Precision Oncology.早期平台试验:精准肿瘤学时代剂量探索与治疗筛选的新范式
JCO Precis Oncol. 2019 Oct 24;3. doi: 10.1200/PO.19.00057. eCollection 2019.
3
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.
帕比司他联合或不联合利妥昔单抗治疗复发弥漫性大B细胞淋巴瘤的2期研究。
Blood. 2016 Jul 14;128(2):185-94. doi: 10.1182/blood-2016-02-699520. Epub 2016 May 10.
4
Innovative Clinical Trial Designs: Toward a 21st-Century Health Care System.创新临床试验设计:迈向21世纪医疗保健系统。
Stat Biosci. 2011 Dec;3(2):145-168. doi: 10.1007/s12561-011-9042-5.
5
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.无法切除或多灶性胶质母细胞瘤的贝伐珠单抗和替莫唑胺一线治疗的 II 期试验。
Cancer Med. 2013 Apr;2(2):185-95. doi: 10.1002/cam4.58. Epub 2013 Jan 24.
6
Integrated phase II/III clinical trials in oncology: a case study.肿瘤学中的整合 II/III 期临床试验:案例研究。
Clin Trials. 2012 Dec;9(6):741-7. doi: 10.1177/1740774512464724. Epub 2012 Nov 22.
7
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study.厄洛替尼在首次复发胶质母细胞瘤中的安全性和疗效:一项开放标签的 II 期研究。
Neuro Oncol. 2010 Oct;12(10):1061-70. doi: 10.1093/neuonc/noq072. Epub 2010 Jul 8.
8
A review of phase 2-3 clinical trial designs.2-3期临床试验设计综述。
Lifetime Data Anal. 2008 Mar;14(1):37-53. doi: 10.1007/s10985-007-9049-x. Epub 2007 Sep 2.
9
Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.顺铂/卡铂+依托泊苷+长春瑞滨治疗晚期非小细胞肺癌:一项多中心随机试验。坎帕尼亚肿瘤学组
Br J Cancer. 1996 Dec;74(11):1805-11. doi: 10.1038/bjc.1996.634.
10
Basic design considerations for clinical trials in oncology.肿瘤学临床试验的基本设计考量
Jpn J Cancer Res. 1992 Jun;83(6):547-58. doi: 10.1111/j.1349-7006.1992.tb00124.x.